EUVIMEDEUVIMED entdecken
Open Access

A genetic variant in SMAD7 acts as a modifier of LMNA -associated muscular dystrophy, implicating SMAD signaling as a therapeutic target

Nathaniel P Mohar iD, Christopher J Langland iD, Zachary Darr iD, Jill Viles, Steven A Moore, Benjamin W Darbro iD, Lori L Wallrath iD

Science Advances · 2025

DOI: 10.1126/sciadv.ads7903 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Science Advances, 2025. Verfasst von Nathaniel P Mohar und 6 weiteren Autor:innen. Beteiligte Einrichtung: Interdisciplinary Graduate Program in Genetics, University of Iowa, Iowa City, IA 52242, USA. Hauptthemen laut MEDLINE: Smad7 Protein, Lamin Type A, Signal Transduction, Muscular Dystrophies. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 102 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NINDS NIH HHS, NIAMS NIH HHS, NIGMS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Mutations in LMNA cause multiple types of muscular dystrophy ( LMNA -MD). The symptoms of LMNA -MD are highly variable and sensitive to genetic background. To identify genetic contributions to this phenotypic variability, we performed whole-genome sequencing on four siblings possessing the same LMNA mutation with differing degrees of skeletal muscle disease severity. We identified a variant in SMAD7 that segregated with severe muscle disease. To functionally test the SMAD7 variant, we generated a Drosophila model possessing the LMNA mutation and the SMAD7 variant in the orthologous fly genes. The SMAD7 variant increased SMAD signaling and enhanced muscle defects caused by the mutant lamin. Conversely, overexpression of wild-type SMAD7 rescued muscle function. These findings were extended to humans by showing that SMAD signaling is increased in muscle biopsy tissue from individuals with LMNA -MD compared to age-matched controls. Collectively, our findings support SMAD7 as the first functionally tested genetic modifier for LMNA -MD and suggest components of the SMAD pathway as therapeutic targets.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Smad7 ProteinLamin Type ASignal TransductionMuscular DystrophiesAnimalsHumansMaleFemaleMutationMuscle, SkeletalDisease Models, AnimalAdult

Substanzen

Smad7 ProteinLamin Type ALMNA protein, humanSMAD7 protein, human

Autor:innen und Institutionen

  • Interdisciplinary Graduate Program in Genetics, University of Iowa, Iowa City, IA 52242, USA.
  • Department of Biochemistry and Molecular Biology, Carver College of Medicine, University of Iowa, Iowa City, IA 52242, USA.
  • Independent researcher, Gowrie, Iowa, USA.
  • Department of Pathology, Carver College of Medicine, University of Iowa, Iowa City, IA 52242, USA.
  • Department of Pediatrics, Carver College of Medicine, University of Iowa, Iowa City, IA 52242, USA.

ORCID-Profile: Nathaniel P Mohar, Christopher J Langland, Zachary Darr, Benjamin W Darbro, Lori L Wallrath

Förderung

  • NINDS NIH HHS
  • NIAMS NIH HHS
  • NIGMS NIH HHS

Zitieren

APA

Mohar, N. P., Langland, C. J., Darr, Z., Viles, J., Moore, S. A., Darbro, B. W., & Wallrath, L. L. (2025). A genetic variant in SMAD7 acts as a modifier of LMNA -associated muscular dystrophy, implicating SMAD signaling as a therapeutic target. Science Advances. https://doi.org/10.1126/sciadv.ads7903

Vancouver

Mohar NP, Langland CJ, Darr Z, Viles J, Moore SA, Darbro BW, et al. A genetic variant in SMAD7 acts as a modifier of LMNA -associated muscular dystrophy, implicating SMAD signaling as a therapeutic target. Science Advances. 2025. doi:10.1126/sciadv.ads7903

BibTeX
@article{Mohar2025,
  author = {Mohar, Nathaniel P and Langland, Christopher J and Darr, Zachary and Viles, Jill and Moore, Steven A and Darbro, Benjamin W and Wallrath, Lori L},
  title = {A genetic variant in SMAD7 acts as a modifier of LMNA -associated muscular dystrophy, implicating SMAD signaling as a therapeutic target},
  journal = {Science Advances},
  year = {2025},
  doi = {10.1126/sciadv.ads7903}
}
Kostenlos starten →